# Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine

> **NCT00796991** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 72 (actual)

## Conditions studied

- Advanced Melanoma

## Interventions

- **DRUG:** Ipilimumab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Dacarbazine

## Key facts

- **NCT ID:** NCT00796991
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2009-11
- **Final completion:** 2012-10
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2014-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00796991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00796991, "Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00796991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*